Temoporfin

Temoporfin

Systematic (IUPAC) name
3,3',3'',3'''-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
Clinical data
AHFS/Drugs.com	International Drug Names
License data	EU EMA: Foscan
Legal status	℞ (Prescription only)
Identifiers
CAS Number	122341-38-2
ATC code	L01XD05 (WHO)
PubChem	CID 60751
ChemSpider	54754
UNII	FU21S769PF
KEGG	D06066
ChEMBL	CHEMBL383675
Chemical data
Formula	C44H32N4O4
Molar mass	680.74 g/mol
SMILES c1cc(cc(c1)O)c2/c3ccc([nH]3)/c(c/4\nc(/c(c\5/cc/c(/[nH]5)c(/c6n\c2\CC6)\c7cccc(c7)O)/c8cccc(c8)O)C=C4)/c9cccc(c9)O
InChI InChI=1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40- Key:LYPFDBRUNKHDGX-LWQDQPMZSA-N
(verify)

Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck^[1] .^[2] It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.^[3]

Good results were obtained in 21 of 35 patients treated in Germany.^[4]

It is photoactivated at 652 nm^[5] i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.^[2]

Further reading

• Relationship between subcellular localisation of Foscan and caspase activation in photosensitised MCF-7 cells. Marchal et al. 2007

References

1. Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". HNO (in German) 56 (4): 402–9. doi:10.1007/s00106-007-1573-1. PMID 17516041.
2. O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology.
3. http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
4. http://www.springerlink.com/content/g74w224824v8l013/
5. "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009.